The tumour microenvironment and implications for cancer immunotherapy

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2006-06-29

• Fields of study

  Biology, Medicine, Chemistry, Environmental Science

• Identifiers
  DOI 10.1517/14712598.6.7.671PMID 16805707
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Maximal COX‐2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma

  2006influential reference
• Local Delivery of Vaccinia Virus Expressing Multiple Costimulatory Molecules for the Treatment of Established Tumors

  2006cited by this paper
• CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine1

  2006cited by this paper
• Tumor-infiltrating T lymphocytes: friends or foes?

  2006influential reference
• TGF-β in cancer and as a therapeutic target

  2006cited by this paper
• Tumor-derived CD4+CD25+ regulatory T cell suppression of dendritic cell function involves TGF-β and IL-10

  2006influential reference
• Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis.

  2006cited by this paper
• Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma.

  2006cited by this paper
• IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.

  2006cited by this paper
• Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.

  2006cited by this paper
• Hypoxia and anemia: effects on tumor biology and treatment resistance.

  2005influential reference
• Combination B7-Fc Fusion Protein Treatment and Treg Cell Depletion Therapy

  2005cited by this paper
• Targeted therapies in the treatment of colorectal cancers.

  2005cited by this paper
• Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer.

  2005influential reference
• Anti-angiogenic therapy as a cancer treatment paradigm.

  2005cited by this paper
• Targeted Cancer Therapy Using Radiolabeled Monoclonal Antibodies

  2005cited by this paper
• Regulatory T Cells in Ovarian Cancer: Biology and Therapeutic Potential

  2005cited by this paper
• Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

  2005cited by this paper
• Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity

  2005cited by this paper
• Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies.

  2005cited by this paper
• Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel

  2005influential reference
• Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma

  2005cited by this paper
• Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

  2005cited by this paper
• Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.

  2005cited by this paper
• High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

  2005cited by this paper
• GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

  2005cited by this paper
• Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells

  2005cited by this paper
• Immune responses to p53 in patients with cancer:enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites

  2005cited by this paper
• Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.

  2005cited by this paper
• Indoleamine 2,3 dioxygenase and regulation of T cell immunity.

  2005cited by this paper
• Manipulating the Local Tumor Microenvironment with Poxviruses Expressing Costimulatory Molecules

  2005cited by this paper
• Stromal fibroblasts in cancer initiation and progression

  2004cited by this paper
• Purification and Characterization of Mouse Soluble Receptor for Advanced Glycation End Products (sRAGE)*

  2004influential reference
• Intratumoral Administration of Dendritic Cells Overexpressing CCL21 Generates Systemic Antitumor Responses and Confers Tumor Immunity

  2004cited by this paper
• Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses

  2004cited by this paper
• S100A7 and the progression of breast cancer

  2004cited by this paper
• Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

  2004cited by this paper
• Local Administration of Granulocyte/Macrophage Colony-stimulating Factor Increases the Number and Activation State of Dendritic Cells in the Sentinel Lymph Node of Early-Stage Melanoma

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules

  2004cited by this paper
• Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector

  2004cited by this paper
• Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

  2004cited by this paper
• Relevance of tumor microenvironment for progression, therapy and drug development.

  2004cited by this paper
• Visualization of naturally occurring Foxp3+ regulatory T cells in normal and tumor-bearing mice.

  2004cited by this paper
• The Interleukin (IL)‐2 Family Cytokines: Survival and Proliferation Signaling Pathways in T Lymphocytes

  2004cited by this paper
• S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma.

  2004cited by this paper
• Reduced T-Cell and Dendritic Cell Function Is Related to Cyclooxygenase-2 Overexpression and Prostaglandin E2 Secretion in Patients With Breast Cancer

  2004cited by this paper
• Angiogenesis in health and disease

  2003cited by this paper
• MHC class I antigens, immune surveillance, and tumor immune escape

  2003cited by this paper
• l-Arginine Consumption by Macrophages Modulates the Expression of CD3ζ Chain in T Lymphocytes1

  2003cited by this paper
• EBV-Induced Molecule 1 Ligand Chemokine (ELC/CCL19) Promotes IFN-γ-Dependent Antitumor Responses in a Lung Cancer Model

  2003cited by this paper
• Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors.

  2003cited by this paper
• 22. Immune responses to malignancies.

  2003cited by this paper
• Microenvironmental and cellular consequences of altered blood flow in tumours.

  2003influential reference
• Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

  2003cited by this paper
• Induction of tumor-specific T cell memory by NK cell–mediated tumor rejection

  2002cited by this paper
• Role of angiogenesis in tumor growth and metastasis.

  2002cited by this paper
• Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1

  2002cited by this paper
• Reversal of Tumor-induced Dendritic Cell Paralysis by CpG Immunostimulatory Oligonucleotide and Anti–Interleukin 10 Receptor Antibody

  2002cited by this paper
• CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2.

  2002cited by this paper
• Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy

  2001cited by this paper
• Know thy neighbor: stromal cells can contribute oncogenic signals.

  2001cited by this paper
• Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer.

  2001cited by this paper
• Immunoglobulin genes expressed by B-lymphocytes infiltrating cervical carcinomas show evidence of antigen-driven selection

  2001cited by this paper
• Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

  2001cited by this paper
• Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function.

  2001cited by this paper
• The number of intratumoral dendritic cells and ζ‐chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma

  2001cited by this paper
• Inhibition of Activated/Memory (CD45RO+) T Cells by Oxidative Stress Associated with Block of NF-κB Activation1

  2001cited by this paper
• The relative role of ErbB1–4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells

  2001influential reference
• Regression of Engineered Tumor Cells Secreting Cytokines Is Related to a Shift in Host Cytokine Profile from Type 2 to Type 1

  2000cited by this paper
• Arginase activity in human breast cancer cell lines: N(omega)-hydroxy-L-arginine selectively inhibits cell proliferation and induces apoptosis in MDA-MB-468 cells.

  2000cited by this paper
• Characterization of intracellular cytokine profile of CD4(+) T cells in peripheral blood and tumor-draining lymph nodes of patients with gastrointestinal cancer.

  2000cited by this paper
• Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.

  2000cited by this paper
• Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth.

  2000cited by this paper
• Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.

  2000cited by this paper
• Cytokine profiles in spontaneously regressing basal cell carcinomas

  2000cited by this paper
• Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy.

  2000cited by this paper
• IL‐12‐ and IL‐2‐induced tumor regression in a new murine model of oral squamous‐cell carcinoma is promoted by expression of the CD80 co‐stimulatory molecule and interferon‐γ

  2000cited by this paper
• Poor clinical outcome of patients with Hodgkin's Disease and elevated interleukin-10 serum levels

  2000cited by this paper
• High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

  1999cited by this paper
• Alterations in proteolytic activity at low pH and its association with invasion: A theoretical model

  1999cited by this paper
• Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.

  1999cited by this paper
• Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection.

  1999cited by this paper
• IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response

  1999cited by this paper
• The expression of transforming growth factor‐β1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma

  1999cited by this paper
• British Journal of Cancer

  1999cited by this paper
• Arginase and ornithine, as markers in human non-small cell lung carcinoma.

  1999cited by this paper
• Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.

  1999cited by this paper
• Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes.

  1998cited by this paper
• Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival.

  1998cited by this paper
• Minimal recruitment and activation of dendritic cells within renal cell carcinoma.

  1998cited by this paper
• Natural killer cells and tumor therapy.

  1998influential reference
• The role of Fas/FasL in immunosuppression induced by human tumors

  1998cited by this paper
• Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes.

  1998cited by this paper
• Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1.

  1998cited by this paper
• Prevention of allogeneic fetal rejection by tryptophan catabolism.

  1998cited by this paper
• Mechanisms responsible for signaling and functional defects.

  1998influential reference
• Study of tumor infiltrating lymphocytes and transforming growth factor‐β as prognostic factors in breast carcinoma

  1997cited by this paper
• T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas.

  1997cited by this paper
• Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer.

  1997cited by this paper

• The role of cytokines in shaping the future of Cancer immunotherapy.

  2025cites this paper
• FoxP3+ Regulatory T-Cell Quantities in Nodal T-Follicular Helper Cell Lymphomas and Peripheral T-Cell Lymphomas Not Otherwise Specified and Their Impact on Overall Survival

  2024cites this paper
• State-dependent evolutionary models reveal modes of solid tumour growth

  2022cites this paper
• The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers

  2022cites this paper
• TCR-like antibodies in cancer immunotherapy

  2019cites this paper
• Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

  2018cites this paper
• Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein

  2017cites this paper
• Stromal Fibroblasts from the Interface Zone of Triple Negative Breast Carcinomas Induced Epithelial-Mesenchymal Transition and its Inhibition by Emodin

  2017cites this paper
• Biomarkers of prognosis and toxicity for metastatic melanoma patients treated with ipilimumab

  2017cites this paper
• Host stromal versican is essential for cancer‐associated fibroblast function to inhibit cancer growth

  2016cites this paper
• Mesenchymal Stem/Stromal Cell-Targeted Therapies for Solid Tumors and Hematological Malignancies

  2015cites this paper
• Formulation, characterization and validation of CpG functionalized PLGA bacteriomimetic nanoparticles for breast cancer immunotherapy

  2015cites this paper
• Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy

  2015cites this paper
• Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.

  2015cites this paper
• Quantitative proteomic analysis of paired colorectal cancer and non-tumorigenic tissues reveals signature proteins and perturbed pathways involved in CRC progression and metastasis.

  2015cites this paper
• MSCs in Solid Tumors and Hematological Malignancies: From Basic Biology to Therapeutic Applications

  2013cites this paper
• Investigating breast cancer O-linked glycosylation changes and their immunotherapeutic potential

  2013cites this paper
• Cytokines in the Treatment of Cancer

  2013cites this paper
• Microenvironment and Immunology Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells

  2012cites this paper
• Targeting Tumor Microenvironments for Cancer Prevention and Therapy

  2012cites this paper
• Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells.

  2012cites this paper
• Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape

  2012cites this paper
• Recombinant heat shock protein 70 in combination with radiotherapy as a source of tumor antigens to improve dendritic cell immunotherapy

  2012cites this paper
• Cytotoxic T cells - stroma interactions.

  2011cites this paper
• Immune cell infiltration of primary and metastatic lesions: mechanisms and clinical impact.

  2011cites this paper
• Decrease in CD8+ lymphocyte number and altered cytokine profile in human prostate cancer.

  2011cites this paper
• Decrease in CD 8 + lymphocyte number and altered cytokine profile in human prostate cancer

  2011cites this paper
• Brief Communication Decrease in CD8+ lymphocyte number and altered cytokine profile in human prostate cancer

  2011cites this paper
• Encapsulated cells to focus the metabolic activation of anticancer drugs.

  2010cites this paper
• Pathogenesis of B-cell post-transplant lymphoproliferative disorders and HIV-associated B-cell lymphomas

  2010cites this paper
• Mesenchymal Stem/Stromal Cells as Cellular Vehicles for Tumor Targeting

  2010cites this paper
• Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment.

  2009cites this paper
• Identification of EpCAM as a molecular target of prostate cancer stroma.

  2009cites this paper
• Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression

  2009cites this paper
• Combination of immunotherapy with anaerobic bacteria for immunogene therapy of solid tumours

  2009cites this paper
• An Agent-Based Model of Solid Tumor Progression

  2009cites this paper
• Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma

  2008cites this paper
• Cancer immunotherapy: perspectives and prospects.

  2008cites this paper
• Cytokine therapy in cancer

  2008cites this paper
• Models of Pancreatic Cancer: Understanding Disease Progression

  2008cites this paper
• Granulocyte‐macrophage colony stimulating factor induces endothelial capillary formation through induction of membrane‐type 1 matrix metalloproteinase expression in vitro

  2008cites this paper
• Tumor-specific dendritic cells generated by genetic redirection of Toll-like receptor signaling against the tumor-associated antigen, erbB2

  2007cites this paper
• Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors

  2007cites this paper
• Cytokine therapy for cancer.

  2007cites this paper
• Roadmap for new opportunities in melanoma research.

  2007cites this paper
• Identifying molecular targets for cancer therapy

  2007cites this paper
• Global Expression Analysis of Prostate Cancer-associated Stroma and Epithelia

  2007cites this paper